Innovative Research Award
Ahmet Genç
Antalya Training and Research Hospital, Turkey
Ahmet Genç is a Turkish cardiologist whose clinical and academic activities focus primarily on heart failure, cardiovascular outcomes research, inflammatory biomarkers, electrophysiology, and interventional cardiology. His work combines patient-centered clinical practice with participation in multinational clinical trials and peer-reviewed scientific publications. His contributions include investigator roles in international Phase III cardiovascular studies together with original research addressing prognostic biomarkers, heart failure management, vascular disease, and neurological-cardiovascular interactions.[1]
Abstract
Ahmet Genç has developed an academic profile centered on cardiovascular medicine with particular emphasis on heart failure, prognostic biomarkers, cardiovascular imaging, vascular intervention, and evidence-based clinical management. His publication record includes original investigations, registry analyses, multicenter clinical trials, and collaborative international studies published in leading cardiovascular journals including The Lancet, European Journal of Heart Failure, and other peer-reviewed journals. His participation in global cardiovascular trials demonstrates engagement in translating clinical evidence into improved patient care.[2]
Keywords
Heart Failure, Cardiology, Cardiovascular Medicine, Clinical Research, Biomarkers, Vericiguat, Heart Failure with Reduced Ejection Fraction, Cardiovascular Outcomes, Interventional Cardiology, Prognostic Indicators, Clinical Trials, Cardiovascular Risk.
Introduction
Graduating from Istanbul University Cerrahpaşa Faculty of Medicine in 2001, Ahmet Genç pursued specialization in cardiology and subsequently served in several Turkish hospitals before joining Antalya Training and Research Hospital. Throughout his professional career he has integrated routine cardiovascular care with scientific investigation, particularly in chronic heart failure, acute coronary syndromes, vascular disease, and electrophysiology. His experience spans both public and private healthcare institutions while maintaining an active role in academic publishing and clinical research.[1]
Research Profile
Ahmet Genç has completed Good Clinical Practice training through the Turkish Clinical Research Infrastructure Network and has served as an investigator in major international Phase III clinical trials evaluating novel cardiovascular therapies. His research interests encompass heart failure prognosis, inflammatory biomarkers, cardiovascular pharmacotherapy, neurocardiology, endothelial dysfunction, myocardial infarction outcomes, carotid artery disease, and evidence-based cardiovascular medicine.[2]
Research Contributions
- Participation as investigator in multinational Phase III heart failure clinical trials evaluating vericiguat.
- Research on prognostic biomarkers including NT-proBNP, troponin, vitamin D, uric acid, and inflammatory indices.
- Studies investigating sex differences and long-term outcomes in heart failure.
- Contributions to nationwide myocardial infarction registry analyses.
- Clinical investigations involving endothelial dysfunction, carotid artery stenting, vagal nerve stimulation, and cardiovascular imaging.[4]
Publications
Ahmet Genç’s notable publications are collaborative articles in The Lancet describing outcomes from the VICTOR clinical trial and pooled analyses of vericiguat across heart failure populations. Additional publications examine prognostic biomarkers in chronic heart failure, inflammatory indices in unstable angina, sex differences in cardiovascular outcomes, neurological modulation of heart rate variability, carotid interventions, myocardial infarction registries, endothelial function, and cardiovascular epidemiology.[3]
Research Impact
Ahmet Genç has authored 36 indexed publications receiving 272 citations with an h-index of 9. His collaborations with international investigators and participation in multicenter randomized clinical trials contribute to contemporary understanding of chronic heart failure management and cardiovascular therapeutics. His work has been disseminated through internationally recognized cardiovascular journals and collaborative research networks.[1] [5]
Award Suitability
Ahmet Genç demonstrates sustained engagement in cardiovascular research through clinical investigation, peer-reviewed publications, international collaboration, and evidence-based medicine. His participation in major randomized clinical trials together with original contributions addressing heart failure prognosis, cardiovascular biomarkers, and patient outcomes reflects characteristics commonly associated with recognition in research excellence programs such as the Business Global Awards.[2]
Conclusion
Ahmet Genç has established a balanced career integrating clinical cardiology, investigator-led clinical trials, and scholarly publication. His research addresses important questions in heart failure, cardiovascular risk assessment, and therapeutic optimization while contributing to international collaborative science. Collectively, his academic activities demonstrate a consistent commitment to advancing cardiovascular medicine through clinical evidence and multidisciplinary research.[3] [5]
External Links
References
- Elsevier. (n.d.). Scopus Author Details: Ahmet Genç, Author ID 57222643778.
https://www.scopus.com/authid/detail.uri?authorId=57222643778
- Ahmet Genç., et al. (2022). Factors associated with prolonged prehospital delay in patients with acute myocardial infarction.
https://www.sciencedirect.com/science/article/pii/S1109966622000537
- Ahmet Genç., et al. (2008). Factors associated with prolonged prehospital delay in patients with acute myocardial infarction).
https://pdf.journalagent.com/tkd/pdfs/TKDA_36_3_156_162.pdf
- Ahmet Genç., et al. (2018). The value of STAF (score for the targeting of atrial fibrillation) in patients with cryptogenic embolic stroke.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6563868/
- Ahmet Genç., et al. (2022). Asymptomatic cerebral emboli following carotid artery stenting: a diffusion-weighted MRI study.
https://pmc.ncbi.nlm.nih.gov/articles/PMC9366430/